Research Reports | Market Assessment
March 2022

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) – 2022

The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report (newly diagnosed patients, recently treated patients, persistency, and compliance). The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

This dashboard is included as part of the Treatment Algorithms: Claims Data Analysis Chronic Inducible Urticaria 2022 report, and covers a study period extending through Q2 2021.

Table of contents

  • Urticaria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US) - 2022
    • Abstract
    • Treatment Algorithms CDA Chronic Inducible Urticaria US March 2022
    • Treatment Algorithms CDA Chronic Inducible Urticaria (US) 2022 Dashboard
Shubhendu Ghosh, Ph.D.
Shubhendu Ghosh, Ph.D.

Shubhendu Ghosh, Ph.D., is a senior business insights analyst on the Immune and Inflammatory Disorders team at Clarivate. His focus is the asthma therapy market. Previously, Dr. Ghosh was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports